BioNTech SE Shareholders Approve All Agenda Items at the Annual General Meeting 2026
Rhea-AI Summary
BioNTech (Nasdaq:BNTX) held its 2026 Annual General Meeting, with 92% of share capital represented and all agenda items approved by shareholders.
The Supervisory Board was expanded from six to eight members, adding oncology and commercialization expertise, with Helmut Jeggle elected Chairman and several member mandates extended.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Positive
- High AGM turnout with 92% of share capital represented
- All 2026 AGM agenda items approved by a shareholder majority
- Supervisory Board expanded from six to eight members
- Election of two new Supervisory Board members with oncology and commercialization expertise
- Mandates of three existing Supervisory Board members extended
- Helmut Jeggle elected as Supervisory Board Chairman
Negative
- None.
News Market Reaction – BNTX
On the day this news was published, BNTX declined 0.78%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 07 | Share repurchase plan | Positive | -2.4% | Authorized new ADS repurchase program of up to $1.0 billion. |
| May 05 | Q1 2026 earnings | Negative | -3.9% | Reported Q1 loss with lower revenues and reiterated 2026 guidance. |
| Apr 21 | Earnings date set | Neutral | +6.1% | Announced timing and access details for Q1 2026 earnings call. |
| Mar 24 | Clinical data update | Positive | -1.8% | Presented late‑stage lung cancer data, including a 54% death‑risk reduction. |
| Mar 10 | FY 2025 earnings | Negative | -17.9% | Reported FY 2025 loss with 2026 guidance and oncology readout plans. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent substantive announcements (earnings, clinical data, buyback) often saw negative price reactions, with only the earnings-date notice drawing a clearly positive move.
Over the last few months, BioNTech reported sizeable full-year 2025 revenues and cash, guided 2026 revenues, and highlighted a broad late‑stage oncology pipeline. Subsequent Q1 2026 results showed lower revenues and a net loss alongside a planned $1.0bn ADS repurchase and manufacturing consolidation. A lung‑cancer data update and the new buyback authorization both met with negative price reactions. Today’s AGM approvals fit into this ongoing strategic pivot toward oncology and capital‑return discipline.
Key Terms
supervisory board regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
MAINZ, Germany, May 15, 2026 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) held its Annual General Meeting (“AGM”) today. A total of 92 per cent of the share capital was represented at the virtual assembly. All resolutions proposed on the agenda items put to the vote at today’s AGM were approved by a majority of the shareholders.
BioNTech is strengthening its focus on the Company’s growing late-stage oncology pipeline, while continuing its discovery and early research aimed at long-term innovation. Consequently, the Company's shareholders approved expanding the Supervisory Board from six to eight members and adding additional expertise: Prof. Iris Löw-Friedrich, M.D., Ph.D., and Susanne Schaffert, Ph.D., were elected as new members of the Supervisory Board.
Iris Löw-Friedrich has many years of expertise in the field of clinical development and broad experience in the scientific and medical fields. She also possesses knowledge in the areas of sales and commercialization, management, innovation, and international markets relevant to the Company.
She is an experienced Supervisory Board member and adjunct professor of internal medicine at the faculty of medicine at Goethe University in Frankfurt am Main, Germany.
Susanne Schaffert is a member of supervisory boards in the healthcare sector, including that of Merck KGaA. She possesses particular expertise in the field of oncology as well as in sales and commercialization with a focus on product launches. Her knowledge spans innovation, research and development, and organizational leadership and management.
Additionally, shareholders approved the extension of the mandates of BioNTech’s Supervisory Board members Helmut Jeggle, Prof. Anja Morawietz, Ph.D., and Prof. Rudolf Staudigl, Ph.D.
At a meeting held following the AGM, the Supervisory Board elected Helmut Jeggle as its Chairman.
The voting results for all agenda items can be viewed on the Annual General Meeting 2026 website under the section ‘Voting Results’. The speeches by Chief Executive Officer Prof. Ugur Sahin, M.D., Chief Financial Officer Ramón Zapata and the slides presented at the AGM 2026 can be found in section ‘Speeches and Presentations’ under the same link.
About BioNTech
BioNTech is a global next generation biopharmaceutical company pioneering novel investigative therapies for cancer and other serious diseases. In oncology, BioNTech is committed to transforming how cancer is treated. Its ambition is to develop innovative medicines with pan-tumor or synergistic potential to address cancer from multiple angles and across the full continuum of the disease from early- to late-stage. Its growing late-stage oncology pipeline comprises complementary treatment approaches spanning immunomodulators, antibody drug conjugates, and mRNA cancer immunotherapies. BioNTech has partnered with multiple global and specialized pharmaceutical collaborators leveraging complementary expertise and resources to accelerate innovation and drive progress, including Bristol Myers Squibb, Duality Biologics, Genentech, a member of the Roche Group, Genmab, MediLink, OncoC4, and Pfizer.
For more information, please visit www.BioNTech.com.
BioNTech Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements concerning the potential benefits of appointed Supervisory Board members. In some cases, forward-looking statements can be identified by terminology such as “will,” “may,” “should,” “expects,” “intends,” “plans,” “aims,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” “continue,” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words.
The forward-looking statements in this press release are based on BioNTech’s current expectations and beliefs of future events and are neither promises nor guarantees. You should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond BioNTech’s control, and which could cause actual results to differ materially and adversely from those expressed or implied by these forward-looking statements.
You should review the risks and uncertainties described under the heading “Risk Factors” in BioNTech’s Report on Form 6-K for the period ended March 31, 2026, and in subsequent filings made by BioNTech with the SEC, which are available on the SEC’s website at www.sec.gov. These forward-looking statements speak only as of the date hereof. Except as required by law, BioNTech disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise.
CONTACTS
Investor Relations
Douglas Maffei, PhD
Investors@biontech.de
Media Relations
Jasmina Alatovic
Media@biontech.de
